Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study
We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels, and identified the most useful marker in patients with ovarian clear cell carcinoma (OCCC). The study included 109 patients with OCCC who did...
Saved in:
Published in | Cancer research and treatment Vol. 48; no. 1; pp. 250 - 258 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
Korean Cancer Association
01.01.2016
대한암학회 |
Subjects | |
Online Access | Get full text |
ISSN | 1598-2998 2005-9256 |
DOI | 10.4143/crt.2014.324 |
Cover
Abstract | We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels, and identified the most useful marker in patients with ovarian clear cell carcinoma (OCCC).
The study included 109 patients with OCCC who did not have any inflammatory conditions except endometriosis, and underwent primary debulking surgery between 1997 and 2012. Leukocyte differential counts (neutrophil, lymphocyte, monocyte, eosinophil, basophil, and platelet), SIR markers including neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), and platelet to lymphocyte ratio (PLR), and CA-125 levels were estimated to select potential markers for clinical outcomes.
Among potential markers (neutrophil, monocyte, platelet, NLR, MLR, PLR, and CA-125 levels) selected by stepwise comparison, CA-125 levels were best at predicting advanced stage disease, suboptimal debulking and platinum-resistance (cut-off values, ≥ 46.5, ≥ 11.45, and ≥ 66.4 U/mL; accuracies, 69.4%, 78.7%, and 68.5%) while PLR ≥ 205.4 predicted non-complete response (CR; accuracy, 71.6%) most accurately. Moreover, PLR < 205.4 was an independent factor for the reduced risk of non-CR (adjusted odds ratio, 0.17; 95% confidence interval [CI], 0.04 to 0.69), and NLR < 2.8 was a favorable factor for improved progression-free survival (PFS; adjusted hazard ratio, 0.49; 95% CI, 0.25 to 0.99) despite lack of a marker for overall survival among the potential markers.
CA-125 levels may be the most useful marker for predicting advanced-stage disease. Suboptimal debulking and platinum-resistance, and PLR and NLR may be most effective to predict non-CR and PFS in patients with OCCC. |
---|---|
AbstractList | PURPOSEWe compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels, and identified the most useful marker in patients with ovarian clear cell carcinoma (OCCC).MATERIALS AND METHODSThe study included 109 patients with OCCC who did not have any inflammatory conditions except endometriosis, and underwent primary debulking surgery between 1997 and 2012. Leukocyte differential counts (neutrophil, lymphocyte, monocyte, eosinophil, basophil, and platelet), SIR markers including neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), and platelet to lymphocyte ratio (PLR), and CA-125 levels were estimated to select potential markers for clinical outcomes.RESULTSAmong potential markers (neutrophil, monocyte, platelet, NLR, MLR, PLR, and CA-125 levels) selected by stepwise comparison, CA-125 levels were best at predicting advanced stage disease, suboptimal debulking and platinum-resistance (cut-off values, ≥ 46.5, ≥ 11.45, and ≥ 66.4 U/mL; accuracies, 69.4%, 78.7%, and 68.5%) while PLR ≥ 205.4 predicted non-complete response (CR; accuracy, 71.6%) most accurately. Moreover, PLR < 205.4 was an independent factor for the reduced risk of non-CR (adjusted odds ratio, 0.17; 95% confidence interval [CI], 0.04 to 0.69), and NLR < 2.8 was a favorable factor for improved progression-free survival (PFS; adjusted hazard ratio, 0.49; 95% CI, 0.25 to 0.99) despite lack of a marker for overall survival among the potential markers.CONCLUSIONCA-125 levels may be the most useful marker for predicting advanced-stage disease. Suboptimal debulking and platinum-resistance, and PLR and NLR may be most effective to predict non-CR and PFS in patients with OCCC. Purpose We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels, and identified the most useful marker in patients with ovarian clear cell carcinoma (OCCC). Materials and Methods The study included 109 patients with OCCC who did not have any inflammatory conditions except endometriosis, and underwent primary debulking surgery between 1997 and 2012. Leukocyte differential counts (neutrophil, lymphocyte, monocyte, eosinophil, basophil, and platelet), SIR markers including neutrophil to lymphocyte ratio (NLR), monocyte to lympho- cyte ratio (MLR), and platelet to lymphocyte ratio (PLR), and CA-125 levels were estimated to select potential markers for clinical outcomes. Results Among potential markers (neutrophil, monocyte, platelet, NLR, MLR, PLR, and CA-125 levels) selected by stepwise comparison, CA-125 levels were best at predicting advanced stage disease, suboptimal debulking and platinum-resistance (cut-off values, ! 46.5, ! 11.45, and ! 66.4 U/mL; accuracies, 69.4%, 78.7%, and 68.5%) while PLR ! 205.4 predicted non- complete response (CR; accuracy, 71.6%) most accurately. Moreover, PLR < 205.4 was an independent factor for the reduced risk of non-CR (adjusted odds ratio, 0.17; 95% confi- dence interval [CI], 0.04 to 0.69), and NLR < 2.8 was a favorable factor for improved progression-free survival (PFS; adjusted hazard ratio, 0.49; 95% CI, 0.25 to 0.99) despite lack of a marker for overall survival among the potential markers. Conclusion CA-125 levels may be the most useful marker for predicting advanced-stage disease. Suboptimal debulking and platinum-resistance, and PLR and NLR may be most effective to predict non-CR and PFS in patients with OCCC. KCI Citation Count: 0 We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels, and identified the most useful marker in patients with ovarian clear cell carcinoma (OCCC). The study included 109 patients with OCCC who did not have any inflammatory conditions except endometriosis, and underwent primary debulking surgery between 1997 and 2012. Leukocyte differential counts (neutrophil, lymphocyte, monocyte, eosinophil, basophil, and platelet), SIR markers including neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), and platelet to lymphocyte ratio (PLR), and CA-125 levels were estimated to select potential markers for clinical outcomes. Among potential markers (neutrophil, monocyte, platelet, NLR, MLR, PLR, and CA-125 levels) selected by stepwise comparison, CA-125 levels were best at predicting advanced stage disease, suboptimal debulking and platinum-resistance (cut-off values, ≥ 46.5, ≥ 11.45, and ≥ 66.4 U/mL; accuracies, 69.4%, 78.7%, and 68.5%) while PLR ≥ 205.4 predicted non-complete response (CR; accuracy, 71.6%) most accurately. Moreover, PLR < 205.4 was an independent factor for the reduced risk of non-CR (adjusted odds ratio, 0.17; 95% confidence interval [CI], 0.04 to 0.69), and NLR < 2.8 was a favorable factor for improved progression-free survival (PFS; adjusted hazard ratio, 0.49; 95% CI, 0.25 to 0.99) despite lack of a marker for overall survival among the potential markers. CA-125 levels may be the most useful marker for predicting advanced-stage disease. Suboptimal debulking and platinum-resistance, and PLR and NLR may be most effective to predict non-CR and PFS in patients with OCCC. |
Author | Suh, Dong Hoon Kim, Kidong Choi, Hwa-Young Kim, Yong Beom Song, Yong Sang Lee, Maria Kim, Hee Seung No, Jae Hong Chung, Hyun Hoon |
Author_xml | – sequence: 1 givenname: Hee Seung surname: Kim fullname: Kim, Hee Seung – sequence: 2 givenname: Hwa-Young surname: Choi fullname: Choi, Hwa-Young – sequence: 3 givenname: Maria surname: Lee fullname: Lee, Maria – sequence: 4 givenname: Dong Hoon surname: Suh fullname: Suh, Dong Hoon – sequence: 5 givenname: Kidong surname: Kim fullname: Kim, Kidong – sequence: 6 givenname: Jae Hong surname: No fullname: No, Jae Hong – sequence: 7 givenname: Hyun Hoon surname: Chung fullname: Chung, Hyun Hoon – sequence: 8 givenname: Yong Beom surname: Kim fullname: Kim, Yong Beom – sequence: 9 givenname: Yong Sang surname: Song fullname: Song, Yong Sang |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25761476$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002074218$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNptkc1vEzEQxS1URNPCjTPykQMb_O2YA1K0oiVSUKU2nC3H66Umu3awnaD89zgN5UucRpr5vXmjeRfgLMTgAHiJ0ZRhRt_aVKYEYTalhD0BE4IQbxTh4gxMMFezhig1OwcXOX9FSDAq8TNwTrgUmEkxAfnukIsbvYWL0A9mHE2J6QBvXd7GkB38ZNLGpQxN6GA7bzDhcOn2bsjQB3izN8mbANvBmQRbNwywNcn6EEfzDs7h6nus3VBcHcb7mAq8K7vu8Bw87c2Q3Yuf9RJ8vvqwaj82y5vrRTtfNpbNaGl6wYxhpqOEHG_tSE-xdERKhTnjayskJb20HAm3tkopLpBlQknDMSKMUHoJXp_2htTrjfU6Gv9Qv0S9SXp-u1powhllvKLvT-h2tx5dZ-vRyQx6m_xo0uFB-Pck-Pu6Zq-ZrA-X7LfXNsVvO5eLHn229SMmuLjLGkuBFKEEi4q--tPrl8ljKBUgJ8CmmHNyvba-mOLj0doPGiN9TF7X5PUxeV2Tr6I3_4ge9_4X_wHPe63x |
CitedBy_id | crossref_primary_10_1002_jcla_23947 crossref_primary_10_1159_000504450 crossref_primary_10_1186_s13048_020_00693_w crossref_primary_10_3390_cancers15143607 crossref_primary_10_4143_crt_2016_175 crossref_primary_10_12677_ACM_2023_13112432 crossref_primary_10_2174_1874944502114010162 crossref_primary_10_5604_01_3001_0013_7974 crossref_primary_10_1371_journal_pone_0177520 crossref_primary_10_20473_mog_V31I32023_117_122 crossref_primary_10_18632_oncotarget_20196 crossref_primary_10_3390_ijms222413650 crossref_primary_10_3802_jgo_2017_28_e36 crossref_primary_10_1093_oncolo_oyae325 crossref_primary_10_18231_j_ijogr_2024_004 crossref_primary_10_1155_2017_7943467 crossref_primary_10_1007_s10147_017_1180_4 crossref_primary_10_1016_j_wneu_2020_11_117 crossref_primary_10_3802_jgo_2019_30_e85 crossref_primary_10_5604_01_3001_0054_9810 crossref_primary_10_1016_j_cca_2020_06_034 crossref_primary_10_1186_s13048_019_0544_y crossref_primary_10_1007_s11523_018_0574_1 crossref_primary_10_1177_1533033818791500 crossref_primary_10_2147_CMAR_S312828 crossref_primary_10_1186_s13048_023_01116_2 crossref_primary_10_1016_j_intimp_2017_02_027 crossref_primary_10_1016_j_smhs_2020_10_001 crossref_primary_10_1007_s00261_025_04842_x crossref_primary_10_3389_fonc_2022_1023177 crossref_primary_10_4137_BIC_S28378 crossref_primary_10_18632_oncotarget_7216 crossref_primary_10_3233_CBM_160614 crossref_primary_10_3233_CBM_160658 crossref_primary_10_1097_IGC_0000000000001293 crossref_primary_10_1016_j_ygyno_2017_02_026 crossref_primary_10_1007_s00011_017_1026_6 crossref_primary_10_1007_s00404_018_4678_8 crossref_primary_10_3389_fonc_2018_00078 crossref_primary_10_1136_ijgc_2020_001378 crossref_primary_10_1186_s12905_023_02692_7 crossref_primary_10_1002_jcla_22185 crossref_primary_10_5937_jomb0_46035 crossref_primary_10_1186_s13048_023_01106_4 crossref_primary_10_3389_fonc_2024_1360663 crossref_primary_10_1097_MD_0000000000010180 |
Cites_doi | 10.1016/S0301-2115(96)02662-0 10.1164/ajrccm.159.3.9805087 10.1016/S0090-8258(02)00156-7 10.1007/s12094-011-0687-9 10.1016/j.ygyno.2014.01.026 10.1155/2014/349546 10.1093/jnci/dju124 10.1038/bjc.2011.189 10.3802/jgo.2012.23.4.265 10.1002/jso.20494 10.1016/j.ygyno.2013.11.016 10.1186/1479-5876-10-33 10.1097/IGC.0b013e3182070f17 10.1158/1055-9965.EPI-14-0146 10.1002/ijc.27441 10.1016/j.ejogrb.2007.05.012 10.3802/jgo.2014.25.3.236 10.1007/s00262-008-0516-3 10.5468/ogs.2014.57.5.343 10.1161/ATVBAHA.110.207514 10.1016/S0140-6736(00)04046-0 10.1006/gyno.1998.5071 10.1002/cncr.24152 10.2741/3511 |
ContentType | Journal Article |
Copyright | Copyright © 2016 by the Korean Cancer Association 2016 |
Copyright_xml | – notice: Copyright © 2016 by the Korean Cancer Association 2016 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
DOI | 10.4143/crt.2014.324 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2005-9256 |
EndPage | 258 |
ExternalDocumentID | oai_kci_go_kr_ARTI_254345 PMC4720074 25761476 10_4143_crt_2014_324 |
Genre | Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
GroupedDBID | --- 29B 5-W 53G 8JR 9ZL AAYXX ABDBF ACUHS ACYCR ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK E3Z EBD EF. F5P HYE OK1 RPM TR2 C1A CGR CUY CVF ECM EIF NPM 7X8 5PM 08R M~E |
ID | FETCH-LOGICAL-c483t-f64aa4ad3221476d2f317e27791545bc6732f7c506ebc999560c4697a51024233 |
ISSN | 1598-2998 |
IngestDate | Tue Nov 21 21:37:34 EST 2023 Thu Aug 21 14:10:32 EDT 2025 Fri Jul 11 11:34:45 EDT 2025 Thu Apr 03 06:59:24 EDT 2025 Tue Jul 01 03:18:44 EDT 2025 Thu Apr 24 23:01:20 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Blood platelets Lymphocytes Ovarian neoplasms CA-125 antigen Clear cell adenocarcinoma Neutrophils |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c483t-f64aa4ad3221476d2f317e27791545bc6732f7c506ebc999560c4697a51024233 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 G704-000841.2016.48.1.048 http://dx.doi.org/10.4143/crt.2014.324 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC4720074 |
PMID | 25761476 |
PQID | 1760923216 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_254345 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4720074 proquest_miscellaneous_1760923216 pubmed_primary_25761476 crossref_citationtrail_10_4143_crt_2014_324 crossref_primary_10_4143_crt_2014_324 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-01-01 |
PublicationDateYYYYMMDD | 2016-01-01 |
PublicationDate_xml | – month: 01 year: 2016 text: 2016-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Korea (South) |
PublicationPlace_xml | – name: Korea (South) |
PublicationTitle | Cancer research and treatment |
PublicationTitleAlternate | Cancer Res Treat |
PublicationYear | 2016 |
Publisher | Korean Cancer Association 대한암학회 |
Publisher_xml | – name: Korean Cancer Association – name: 대한암학회 |
References | ref13 ref12 ref15 ref14 ref11 ref10 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref25 ref20 ref22 ref8 ref7 ref9 ref4 ref3 ref6 ref5 Nieswandt (ref21) 1999 24875653 - J Natl Cancer Inst. 2014 Jun;106(6):dju124 21071699 - Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2362-7 22261860 - Int J Cancer. 2012 Jun 15;130(12):2747-60 25264524 - Obstet Gynecol Sci. 2014 Sep;57(5):343-57 19273333 - Front Biosci (Landmark Ed). 2009;14:4044-57 24462730 - Gynecol Oncol. 2014 Mar;132(3):542-50 16550573 - J Surg Oncol. 2006 Apr 1;93(5):379-86 9076425 - Eur J Obstet Gynecol Reprod Biol. 1997 Mar;72(1):73-7 18414853 - Cancer Immunol Immunother. 2009 Jan;58(1):15-23 25050383 - J Immunol Res. 2014;2014:349546 12648592 - Gynecol Oncol. 2003 Mar;88(3):394-9 10096562 - Cancer Res. 1999 Mar 15;59(6):1295-300 9740700 - Gynecol Oncol. 1998 Aug;70(2):255-8 19195045 - Cancer. 2009 Apr 1;115(7):1395-403 24793958 - Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1204-12 22369276 - J Transl Med. 2012;10:33 24333362 - Gynecol Oncol. 2014 Mar;132(3):560-5 25045437 - J Gynecol Oncol. 2014 Jul;25(3):236-48 21775277 - Clin Transl Oncol. 2011 Jul;13(7):499-503 21270624 - Int J Gynecol Cancer. 2011 Feb;21(2):419-23 17644243 - Eur J Obstet Gynecol Reprod Biol. 2008 May;138(1):71-5 21629244 - Br J Cancer. 2011 Jun 28;105(1):93-103 23094130 - J Gynecol Oncol. 2012 Oct;23(4):265-73 10051263 - Am J Respir Crit Care Med. 1999 Mar;159(3):857-63 11229684 - Lancet. 2001 Feb 17;357(9255):539-45 |
References_xml | – ident: ref7 doi: 10.1016/S0301-2115(96)02662-0 – ident: ref10 doi: 10.1164/ajrccm.159.3.9805087 – ident: ref17 doi: 10.1016/S0090-8258(02)00156-7 – ident: ref9 doi: 10.1007/s12094-011-0687-9 – ident: ref12 doi: 10.1016/j.ygyno.2014.01.026 – ident: ref8 doi: 10.1155/2014/349546 – ident: ref24 doi: 10.1093/jnci/dju124 – ident: ref23 doi: 10.1038/bjc.2011.189 – ident: ref13 doi: 10.3802/jgo.2012.23.4.265 – ident: ref5 doi: 10.1002/jso.20494 – ident: ref19 doi: 10.1016/j.ygyno.2013.11.016 – start-page: 1295 volume-title: Lysis of tumor cells by natural killer cells in mice is impeded by platelets year: 1999 ident: ref21 – ident: ref15 doi: 10.1186/1479-5876-10-33 – ident: ref3 doi: 10.1097/IGC.0b013e3182070f17 – ident: ref25 doi: 10.1158/1055-9965.EPI-14-0146 – ident: ref22 doi: 10.1002/ijc.27441 – ident: ref16 doi: 10.1016/j.ejogrb.2007.05.012 – ident: ref1 doi: 10.3802/jgo.2014.25.3.236 – ident: ref14 doi: 10.1007/s00262-008-0516-3 – ident: ref2 doi: 10.5468/ogs.2014.57.5.343 – ident: ref20 doi: 10.1161/ATVBAHA.110.207514 – ident: ref11 doi: 10.1016/S0140-6736(00)04046-0 – ident: ref18 doi: 10.1006/gyno.1998.5071 – ident: ref4 doi: 10.1002/cncr.24152 – ident: ref6 doi: 10.2741/3511 – reference: 24793958 - Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1204-12 – reference: 12648592 - Gynecol Oncol. 2003 Mar;88(3):394-9 – reference: 24333362 - Gynecol Oncol. 2014 Mar;132(3):560-5 – reference: 22369276 - J Transl Med. 2012;10:33 – reference: 23094130 - J Gynecol Oncol. 2012 Oct;23(4):265-73 – reference: 19195045 - Cancer. 2009 Apr 1;115(7):1395-403 – reference: 25050383 - J Immunol Res. 2014;2014:349546 – reference: 21775277 - Clin Transl Oncol. 2011 Jul;13(7):499-503 – reference: 10051263 - Am J Respir Crit Care Med. 1999 Mar;159(3):857-63 – reference: 17644243 - Eur J Obstet Gynecol Reprod Biol. 2008 May;138(1):71-5 – reference: 21629244 - Br J Cancer. 2011 Jun 28;105(1):93-103 – reference: 25045437 - J Gynecol Oncol. 2014 Jul;25(3):236-48 – reference: 11229684 - Lancet. 2001 Feb 17;357(9255):539-45 – reference: 19273333 - Front Biosci (Landmark Ed). 2009;14:4044-57 – reference: 10096562 - Cancer Res. 1999 Mar 15;59(6):1295-300 – reference: 9740700 - Gynecol Oncol. 1998 Aug;70(2):255-8 – reference: 21071699 - Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2362-7 – reference: 25264524 - Obstet Gynecol Sci. 2014 Sep;57(5):343-57 – reference: 24875653 - J Natl Cancer Inst. 2014 Jun;106(6):dju124 – reference: 16550573 - J Surg Oncol. 2006 Apr 1;93(5):379-86 – reference: 22261860 - Int J Cancer. 2012 Jun 15;130(12):2747-60 – reference: 24462730 - Gynecol Oncol. 2014 Mar;132(3):542-50 – reference: 18414853 - Cancer Immunol Immunother. 2009 Jan;58(1):15-23 – reference: 21270624 - Int J Gynecol Cancer. 2011 Feb;21(2):419-23 – reference: 9076425 - Eur J Obstet Gynecol Reprod Biol. 1997 Mar;72(1):73-7 |
SSID | ssj0064371 |
Score | 2.2563124 |
Snippet | We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels,... PURPOSEWe compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125)... Purpose We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125)... |
SourceID | nrf pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 250 |
SubjectTerms | Adult Aged Aged, 80 and over CA-125 Antigen - metabolism Cohort Studies Female Humans Inflammation Mediators - blood Leukocyte Count Middle Aged Odds Ratio Original Ovarian Neoplasms - diagnosis Ovarian Neoplasms - immunology Ovarian Neoplasms - metabolism Prognosis Retrospective Studies Survival Analysis 의약학 |
Title | Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/25761476 https://www.proquest.com/docview/1760923216 https://pubmed.ncbi.nlm.nih.gov/PMC4720074 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002074218 |
Volume | 48 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Cancer Research and Treatment, 2016, 48(1), , pp.250-258 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELe6TUK8IL4pXzISfqpSmsSJbd6StNVADCTUSXuLUs9h1ViKuhYk_nPeuLOTLqk2afASRc7VcfP7Jb47350JeTtScg4TQeApY3CZUReenBvhBX4pdRgVuizR33H0OT485h9PopNe708rammzng_172vzSv4HVWgDXDFL9h-Q3XYKDXAO-MIREIbjrTB25cYXGt7yEpC9cCvmX13Yq7F5OJifi77xLPFAyRh8whghGwL75SdYyfByZ7hvxCBDF16G-wpVy4vCpavPfi2t89fA5eUZqOk26LCzDJwhZ1aDumKQS5Lbhq43WLJJwlKFIRWTMVNjlmRskjGJjVciGUsjpjIropji2KIkk35bBH6cwpWUJYJJaU_iujsVMcnbspLb7lImp9gj9gvnsu3l8He9HFY8a0bqxmO7xvG4FtdTAmLtz7nCHBO3z_XQ2DZbe1UFUeez7Yrf1hpA4IrJ704uHFRLYIReYQiuz4ehS_7u1vDemVs7VbzP9SL_tszPVznYKh9yLEPAoz1yEAiBEQYHSTpOp40agQuqrthv_Rdc1gYO4l17CB19aq9aldeZSrsRvy0Vanaf3KttH5o4Ij8gPVM9JHeO6uiOR-Sy4TNt85k2fKY1nymwjDo-U8dnuqhozWdq-UyRz3TL5_c0ocBm6thMHZupZfNjcjydzLJDr94UxNNchmuvjHlR8OIUJiKfi_g0KEEDNvAIFRoDcx2LMCiFjkaxmWuFedsjzWMlCph80HYIn5D9almZZ4Se8lJL4ysRKsm1Btt_VAhTFoExYBTIsE8GzaPNdV0xHzdu-Z6D5YxA5ABEjkDkAESfsK30D1cp5ga5N4CSJcONpACZBsMcPve4hldUZrm5zH0Rj8AmC_y4T546TLd3Q98BPpM-ER20twJ4v-6VanFmS8pzgWsW_PktxvaC3L16QV-S_fVqY16BYr6ev64p_BePl9Al |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Systemic+Inflammatory+Response+Markers+and+CA-125+Levels+in+Ovarian+Clear+Cell+Carcinoma%3A+A+Two+Center+Cohort+Study&rft.jtitle=Cancer+research+and+treatment&rft.au=%EA%B9%80%ED%9D%AC%EC%8A%B9&rft.au=%EC%B5%9C%ED%99%94%EC%98%81&rft.au=%EC%9D%B4%EB%A7%88%EB%A6%AC%EC%95%84&rft.au=%EC%84%9C%EB%8F%99%ED%9B%88&rft.date=2016-01-01&rft.pub=%EB%8C%80%ED%95%9C%EC%95%94%ED%95%99%ED%9A%8C&rft.issn=1598-2998&rft.eissn=2005-9256&rft.spage=250&rft.epage=258&rft_id=info:doi/10.4143%2Fcrt.2014.324&rft.externalDBID=n%2Fa&rft.externalDocID=oai_kci_go_kr_ARTI_254345 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1598-2998&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1598-2998&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1598-2998&client=summon |